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-patient treatment with calcipotriol 
versus dithranol in refractory psoriasis
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MARIE-JEANNE P. GERRITSEN, PETER C.M. VAN DE KERKHOF
Calcipotriol (50 ug/g) ointment recently became available for the treatment of psoriasis.
Calcipotriol has been shown to be superior to home treatment with dithranol. the time- 
honoured regime of in-patient topical treatment with dithranol in paste or petrolatum for 24 
hours is the gold standard of optimal efficacy of antipsoriatic therapy. This treatment regime 
is adopted in case of insufficient control of psoriasis by out-patient treatments. The aim of 
the present study was to challenge the position of in-patient dithranol treatment. A left-right 
comparative case-control study was designed in ten patients hospitalised with refractory 
psoriasis, comparing classical dithranol treatment and calcipotriol treatment. In contrast to 
what was expected, six of the ten patients showed a more pronounced improvement after 
two weeks at the calcipotriol treated sides. Irritation from caldpofriol was observed in four 
patients after one week and in two patients after two weeks treatment. At the dithranol 
treated sides three of the ten patients showed a better improvement. Four patients experien­
ced irritation after one week and eight patients after two weeks. Irritation due to calcipotriol 
was not associated with an increased irritation due to dithranol, which implies that both 
treatments have a different mechanism of irritation.
The present case-control study indicates that calcipotriol has challenged the untouchable 
superiority of classical in-patient treatment with dithranol. Further studies are indicated to 
improve compliance in out-patient calcipotriol treatment with cream formulations and once 
a aay schedules.
C hronic plaque psoriasis can be treated with various out-patient therapies [1]. However, in patients with extensive, therapy resistant and severely disabling pso­
riasis it is our policy to admit the patient. For this group of 
patients with refractory psoriasis, dithranol so far has been 
the therapy of choice at our in-patient department. Where 
lesions prove to be resistant to this treatment or if new lesions 
continue to appear or in the case of severely itching psoriasis 
various combination approaches are indicated.
Dithranol is a very safe and effective therapy Î2], Previously, 
dithranol has been used in petrolatum [3, 4j and Lassar's 
paste [5], Bioavailability varies significantly with its vehicle 
[6]. Irritation and discoloration of the skin and textiles have
always been limiting its use [7). For homo treatment dithranol 
in a cream base has been developed which is easier to apply 
and wash off and therefore has proved to be more accep­
table [8]. A disadvantage is the lower* efficacy of this formu­
lation [2, 81. In-patient treatment with dithranol in paste or 
petrojatum, however, is the gold standard of therapy, resul­
ting in the clearing of psoriasis in more than 90% of the 
atients within three to five weeks [2]. Dithranol in a cream 
ase at the out-patient department only results in clearing in 
10-35% of the patients in seven to eight weeks ¡2).
Over the last decade vitamin D . analogues have been shown 
to have an important anti-psoriatic effect [9*12]. Recently, 
calcipotriol, 50 }.tg/g in ointment (Daivonex4, LEO Pharma-
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ceuticol Ptocjucls), became available as a routine treatment 
[131. Several comparative studies on the efficacy of calcipo- 
Ino and the classical anti-psoriatic therapies have been car- 
tied out to oluciciote ond ostoblish tho Dosition of colcipoiriol
in dermatology. Betamethasone 17-vaerate [14] and short 
contact dithranol treatment [15] have been compared with 
calcipotriol for efficacy and safely. Calcipotriol proved to be
more effective compared to home treatment wi 
dithranol in a cream base.
In the present study the efficacy of treatment with dithranol 
and calcipotriol was compared in a group of patients with 
severe, therapy-resistant and disabling psoriasis who were, 
for this reason, admitted to our department.
The aim of the present study is to challenge the common 
belief that dithranol is the treatment of choice in severe pso­
riasis. In particular we addressed the following questions: i) 
does calcipotriol have a beneficial effect in severe psoriasis to 
the same extent as dithranol? ii) which aspects limit the use of 
calcipotriol in severe psoriasis?
As this study involves patients with severe psoriasis we set out 
a two weak left-right comparative case-control study to explo­
re the first two weeks of the in-patient treatment phase with 
calcipotriol and dithranol in Lassar's paste or in petrolatum.
Materials and methods
Patients
The investigation was carried out at the in-patient department, 
Patients with extensive and disabling plaque psoriasis, resis­
tant to topical therapy, were admitted and included in the 
study four males and six females were included with ages 
anging from 20*72 years and with a duration of psoriasis 
.tinging from 3 53 years. The patients had used no oral treat­
ment for psoriasis within the six weeks prior to the study 
except for one xitient who had taken fumaric acid. Topical 
treatment was a lowed until the date of submission to the hos­
pital Table I summarises the treatments for psoriasis of the 
patients during six weeks prior to admission. No oral medica­
tion that coula influence the course of psoriasis was allowed. 
Hydroxyzine was allowed for those patients with severe pruri­
tus No additional topical or systemic treatment for psoriasis 
wm permittee! during the trial except for corticosteroids for 
tfm scalp and face
Patients wore treated for two weeks usinq 
subject comparison, One side of the bod' 
dithranol in paste or petrolatum and the other side with calci- 
patriol Which side or the body was treated with what thera­
py was randomly chosen, The regimen for dithranol consisted
Table 1. Previous the rapy
Therapy 6 weeks prior to study
No therapy 1
Topical steroids 5
Calcipotriol 4
Tar 1
Fumaric acid 1
Phototherapy 1
Dithranol
_  _  _ 1
Table II. Scoring for extent and severity of disease
Extent of disease Severity
0 -  no involvement 0 -  no involvement
1 -  < 10% 1 -  slight
2 -10-29% 2 -  moderate
3 -  30-49% 3 -  severe
4 -  50-69% 4 -  severest possible
5 -  70-89%
6-90-100%
or a 24 hour application of dithranol in paste or petrolatum 
in increasing concentrations ranging from 0.05-4%. The 
concentration of dithranol was increased on alternate days. 
Calcipotriol was applied twice daily on lesional skin to a 
maximum of 100 grams per week. Individualisation of the 
treatment with adjunct therapies was postponed until after the 
two weeks7 evaluation. The clinical scores were recorded 
before and after one and two weeks of therapy. Extent and 
severity of the disease were recorded as shown in Table II. 
The extent of the disease was scored as a percentage of 
involved skin. This percentage was transposed into an area 
score. Arms, trunk and legs were scored separately. The seve­
rity of erythema, induration, scaling and pruritus was asses-
recorded usin 
according to 1
£the skin-irritation as a result or tnerapy 
g the 5 point scale. PASI-scores were calci 
ine formula in Table III.
Statistical analysis
Changes in clinical scores and comparisons between the two 
body-sides of the same patients were analysed using the Stu­
dent t-test for paired values.
To obtain insight into the correlation between different para­
meters which characterise the disease, a regression analysis 
was performed (Pearson-r).
t .
t
* * if * k * J 4 ' *
Table III. PASI-score
I 1
I
! Calculation of Hie PASI-score
' .............. ........... ........ .
PASl -  0.2 x A arms x I|E + I + S) + 0.3 x A trunk x I(E  + I + S) + 0.4 x A legs x I(E  + I + S) 
A » Area score
scores
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Results
At the start of the study severity-scores for both body-sides 
were comparable; the average PASI-score was 17.1 ±2 .1  
(mean ± SEM) for the whole body. Both treatment regimens 
induced a statistically significant decrease in PASI-scores after 
one week of treatment (p = 0.0005 for calcipotriol and p = 
0.0003 for dithranol). In the second week of treatment there 
was a significant, further decrease of the PASI-score 
(p = 0.03 ror calcipotriol and p = 0.03 for dithranol) compa­
red to scores after one week, the calcipotriol treated side ten­
ded to respond slightly better to therapy than the dithranol 
treated side but this difference was not statistically significant 
(p = 0.08).
riaure 1 illustrates the difference (A) between the PASI-score 
before and after one and two weeks treatment for the calcipo­
triol and dithranol treated body-sides of the individual 
patients. Before treatment the PASI-scores for both body-sides 
were equal except in one patient (patient 8). After one week 
of therapy, however, three patients showed a therapy respon­
se in favour of dithranol and five patients showed a therapy 
response in favour of calcipotriol. Two patients showed no dif­
ference between the two therapies. After two weeks of therapy 
six patients responded better to the calcipotriol therapy ana 
three patients responded better to the dithranol therapy. In one 
patient there was no difference in response to either therapy. 
Pruritus was experienced in eight out of ten patients before 
treatment. Prior to therapy there was no difference between 
the two body-sides. The scores for pruritus were relatively 
high for psoriasis (2.0 ± 0.4) (mean ± SEM), After one week 
oftherapy a significant decrease of pruritus was experienced 
at the cafcipotnol treated sides (p = 0.003) as well as at the 
dithranol treated sides (p ~ 0.005). In the second week of 
treatment the scores for pruritus still tended to decrease. Cal­
cipotriol was significantly better than dithranol in reducing 
pruritus (p = 0.04 after one week of treatment and p = 0.04 
after the second week of treatment).
After one week of therapy, irritation was seen on both body- 
sides as a result of both therapies, but there was no signifi­
cant difference between the two therapies. The initial irritation 
of calcipotriol tended to decrease in the period between one 
and two weeks. Two out of four patients indicated that irrita­
tion had decreased during continued treatment with calcipo­
triol: the irritation as a result of dithranol treatment increased 
significantly in the second the week of therapy (p = 0,01). 
After two weeks of treatment the mean score for irritation due 
to dithranol was significantly higher than the score for treat­
ment with calcipotriol (p = 0,00o). There was no correlation 
between the scores for irritation on both body-sides in each 
patient after either one or two weeks of treatment. Regression 
analysis revealed that there was no association between pru­
ritus before therapy and irritation as a result of two weeks of 
therapy for either calcipotriol or dithranol.
The mean duration of the in-patient treatment was 5.5 ±0 .7  
(mean ± SEM) weeks. After the two week comparative study, 
coal tar treatment was added for five patients, phototherapy 
with ultraviolet B was added for five patients and photoche­
motherapy for one patient. In three patients oral treatment 
with acitretin had to be added in order to enhance clearing. 
Out of these patients with difficult psoriasis, four patients 
experienced total clearing and the other six patients saw a 
substantial improvement.
Discussion
Most of the investigations on the efficacy and side effects of 
calcipotriol deal with mild to moderate chronic plaque psoria-
Delta PASI
1
2
3
woek 0
wook 1
ajC\
Esc
ua> 0
woek 2 (0a.
»
9
10
-7 ‘i Ì 3 0 1
^-cnlclpouiol heittìr-diUifttiu»! twin*:
Figure l. Delta PASI-score (caldpotriol-dithranof) before 
and after one and two weeks treatment
sis [I]. However Berth Jones et a i [16] reported a group of 
patients with extensive psoriasis; PASI: 18 ± 8.8 [mean t  
SEM). A four week treatment period with calcipotriol ointment 
at home had resulted in a reduction of the PASI-scorc to 7,0 
± 2.0 (mean ± SEM) (61% reduction). Dubertret el a I. (17j 
reported a reduction of the PASI-score from 14.2 t  7.5 
(mean ± SEM) to 8.6 ± 7.5 (mean ± SEM) [39% reduction) 
after two weeks treatment at home with calcipotriol ointment 
In the present study the PASI-scores at the calcipotriol treated 
sides dropped from 8.3 ± 1.0 (mean ± SEM) to 2.9 ± 0 4 
(mean ± SEM) (66% reduction). The difference between the 
present study and the other studies in extensive psoriasis [ 16, 
17] is the setting at the in-patient department in the present 
study and the setting of home treatment in the other studies 
Our figures are indeed analogous to another in-patient study 
on calcipotriol in which patients were treated for two weeks 
with a nigh dose of calcipotriol when a decrease in PASI 
score of 71% was seen [181
An even more pronounced discrepancy has been observed 
between the efficacy of dithranol treatment carried out at in< 
patient departments and home treatment (2j. Dithranol treat 
ment at the in-patient department has been shown to result in 
clearing in 80-100% of the patients [19], whereas dithranol 
treatment at home resulted in clearing in 6 56 - of the 
patients [20, 21 ].
Four out of ten patients in the present study had previously 
been treated witn calcipotriol at home without a satisfactory 
improvement. In these patients in-patient treatment with cold 
potriol resulted in a substantial improvement. The most fea­
sible explanation for the pronounced discrepancy between the 
in-patient and out-patient seting is compliance.
A comparison between home treatment with short contact 
dithranol and calcipotriol revealed that calcipotriol is superior 
with respect to clinical efficacy compared to dithranol (15). 
Comparing dithranol treatment with calcipotriol treatment in 
hospitalised patients a tendency for a superiority of calcipo­
triol over dithranol was observed in me majority of the 
patients in this case-control study. A statistically significant 
superiority of calcipotriol was shown with respect to pruritus. 
These observations challenge the common belief that ¿A hour 
application of dithranol in Lassar's paste or petrolatum is 
superior to any other topical treatment.
Irritation of lesional and perilesional skin was observed in 
four patients at the calcipotriol treated sides after one week's 
treatment. The irritation tended to decrease after two weeks
an
tr eatment. In conti cist to tho habituation to calcipotriol [17] 
uithranol in itation tended to increase after two W66ks of treat- 
merit, in itation os a result of dithranol is supposed to be 
essential ror its anti-psoriatic effect but ¡t is also a less accep­
table adver so event. Tho concentration of dithronol is increa­
sed as a function of the tolerance of the individual patient. 
No coi i elation could be shown between dithranol irritation 
and calcipotrio irritation which suggests that the mechanism 
of irritation is different. It is of interest that those patients who 
experienced pruritus before treatment were not predisposed to 
develop irritation to calcipotriol or dithranol, It is striking to 
see that calcipotriol had a better effect on pruritus th 
dithranol in this group of patients.
In the present study the second phase of the in-patient treat­
ment alter the two-week investigation was difficult to evaluate 
as the strategy was to individualise treatment using combina­
tions which were the most appropriate for the individual 
xitient.
.rom this study it may be concluded that calcipotriol treatment 
at the in-patient department, carried out with care and preci­
sion, is highly effective to the extent that it challenges the 
tinur honoured 24 hour application of dithranol, It is attractive 
to hypothesise that the development of cream formulations 
and once a clay schedules to improve compliance for calcipo- 
Iriol might diminish the gap between efficacy of home treat­
ment and treatment at the in-patient department. ™
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Samenvatting
Caicipotriol zo\i
dktlinq v
opofriol
mtl dtlhranol Applicatie van dithranol in pasta 
gecfurande 24 uur ís heden ten dogen de gouden standaard 
von optimale anti psoriatische therapie ¡n de kliniek. Dit 
bfhandelingsmgime wordt gestart op het moment dat de pso­
riasis thuis níet meer te controleren is.
Hfet doel *
.............— ............. -r i y -----------------------------------
a case controle studie werd ontworpen voor tien 
hènNm met recalcitrante psoriasis. In deze studie werd de 
ssialui, klinische dithronol behandeling vergeleken met cal- 
opofriol ín da kliniek.
in tegenstelling met wat we verwachtten, hadden zes van de 
hm patiënten mt\ sterkere verbetering aan lichaamshelft die 
mttf ccilcipotfiol werd behondeld. Irritatie tengevolge van cal- 
opolriol wos minder dan die van dithranol en was niet geas­
socieerd rrmt mn toegenomen irritatie tengevolge van aithra- 
m 1 hetgeen kon impliceren dat beide therapieën verschillende
mtchantsmen van irritatie hebben.
Dexe easMonlrole studie laat zien dat calcipotnol de verge m-
n UfÄß 31UUIQI I2> UIM U« fJVSHMSï yuii muihuuwi
wordt a#bfuikt in de kliniek uit te dagen* Een links-reents
mei de schijnbaar onaantastbare p 
Uniche behandeiina mef dimranol
«teftjocmdo studies
ihtiiïboHönifeliog ff 
mublies m  « n  ma
_ . . , y  - ,  J .  .  V ,  .  v .
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